Bishopbriggs, United Kingdom

James Redpath


Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 30(Granted Patents)


Location History:

  • Bishopbriggs-Glasgow, GB (1987)
  • Bishopbriggs, GB (1979 - 1994)

Company Filing History:


Years Active: 1979-1994

Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of James Redpath

Introduction

James Redpath is a notable inventor based in Bishopbriggs, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work primarily focuses on developing compounds that address critical health issues, particularly in the treatment of heart failure and bronchoconstriction.

Latest Patents

Among his latest patents, one invention involves the use of a benzo[b]thiopene-2-carboximidamide derivative. This invention relates to the preparation of a medicament suitable for treating heart failure, characterized by high bioavailability without inducing nausea, vomiting, or restlessness. Another significant patent details a method for treating patients suffering from bronchoconstriction, especially during asthmatic attacks. This method utilizes benzothiophene, benzofuran, dihydronaphthalene, or indene derivatives, showcasing his innovative approach to addressing respiratory issues.

Career Highlights

Throughout his career, James Redpath has worked with prominent companies such as Akzo N.V. and Akzona Incorporated. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.

Collaborations

James has collaborated with notable coworkers, including Robert T. Logan and Robert G. Roy. Their combined efforts have likely enhanced the quality and impact of their research and inventions.

Conclusion

James Redpath's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving health outcomes. His work continues to influence the development of effective treatments for critical medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…